2016
DOI: 10.18632/aging.100981 View full text |Buy / Rent full text
|
|

Abstract: Alzheimer's disease is one of the most significant healthcare problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer's disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published [1]. The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neurodegeneration (MEND). Patients who had had… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
94
0
8

Publication Types

Select...

Relationship

0
0

Authors

Journals